Is Wegovy Approved for Weight Loss?
Yes, Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions like hypertension or type 2 diabetes, and in kids 12+ with obesity.[1] It's a GLP-1 receptor agonist that reduces appetite and slows gastric emptying to promote sustained weight loss averaging 15-20% of body weight in trials.
How Does Wegovy Differ from Ozempic?
Both are semaglutide injections from Novo Nordisk, but Wegovy uses higher doses (up to 2.4 mg weekly) for weight loss, while Ozempic maxes at 2 mg for type 2 diabetes. Off-label Ozempic use for weight loss is common due to shortages, but Wegovy is the dedicated option.[1]
Who Qualifies for Wegovy?
Eligibility requires BMI ≥30 (obesity), or BMI ≥27 (overweight) with comorbidities. It's not for cosmetic weight loss or short-term use. Doctors assess via medical history; insurance often covers if criteria met, though prior authorizations are frequent.[1]
What Results Can Users Expect?
In STEP trials, patients lost 12-15% body weight over 68 weeks versus 2-3% on placebo, with greater loss when paired with diet/exercise. Maintenance requires ongoing use—stopping leads to ~2/3 regain within a year.[1]
Common Side Effects and Risks
Nausea (44%), diarrhea (30%), vomiting (24%), and constipation affect most users initially. Rare risks include pancreatitis, gallbladder issues, or thyroid tumors (boxed warning). Heart benefits shown in SELECT trial (20% lower CV events).[1] Monitor for GI intolerance; dose ramps slowly to minimize.
Cost and Access Issues
Weekly self-injection pens cost $1,300-$1,700 without insurance. NovoCare offers savings cards capping copays at $25/month for eligible. Shortages persist, limiting new prescriptions.[1]
When Does Wegovy's Patent Expire?
Core patents on semaglutide expire around 2032 in the US, with formulation patents to 2034-2036. Challenges from Eli Lilly and others are ongoing; generics unlikely before 2032.[2]
[1] FDA.gov - Wegovy Label (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf)
[2] DrugPatentWatch.com - Wegovy Patents (https://www.drugpatentwatch.com/p/tradename/WEGOVY)